Clinical trials: Adult Glioblastoma
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma
This phase I trial is studying the side effects and best dose of cediranib maleate when given together with cilengitide in treating patients with progressive or recurrent glioblastoma.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm
- Trial name
- NCT00979862
- Testing
- Cediranib Maleate, Cilengitide, Laboratory Biomarker Analysis
- Where
- 11 sites in United States
- Volunteers
- 47 people
- Sponsor
- National Cancer Institute (NCI)
CNS Tumor, Adult
Phase I/II Trial of IMA950 Multi-peptide Vaccine Plus Poly-ICLC in Glioblastoma
RATIONALE : IMA 950 is multi tumour-associated peptides (TUMAPs) vaccine, these peptides have been identified on primary glioblastoma multiforme (GBM) cells.
- Trial name
- NCT01920191
- Testing
- IMA 950, Poly ICLC, Immunomonitoring
- Where
- Switzerland
- Volunteers
- 19 people
- Sponsor
- University Hospital, Geneva
Brain Cancer, Glioblastoma
Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)
The goal of this clinical research study is to learn if the combination of bevacizumab and lomustine can help to control glioblastoma. The safety of this combination will also be studied.
- Trial name
- NCT01067469
- Testing
- Standard Dose Bevacizumab, Low Dose Bevacizumab, Lomustine
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- M.D. Anderson Cancer Center